News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.
By Ahmed Aboulenein and Puyaan Singh WASHINGTON, April 22 (Reuters) - Health Secretary Robert F. Kennedy Jr. told a Senate ...
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Stocktwits on MSN
REPL ignites on doctor fury against FDA’s melanoma drug snub — health sec steps back
FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month citing insufficient data to ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $5.04 / share. This is a decrease of 59.94% from the prior estimate of $12.58 dated April 12, 2026. The price ...
LofyGang resurfaces with LofyStealer disguised as Minecraft hack, exfiltrating IBANs and passwords to 24.152.36[.]241, ...
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results